Clinical trials: Biochemically Recurrent Prostate Cancer
Recurrent Prostate Cancer After Surgery
This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the…
- Trial name
- DASBRT-RPC (NCT05946824)
- Testing
- Daily-adaptive Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Prostate Cancer
Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly
The widespread availability of screening coupled with high risks of over diagnosis, over treatment, and a rising risk of dying from competing causes of deaths pose a major challenge for prostate cancer patients and our health…
- Trial name
- NCT00161252
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Biochemical Recurrent Prostate Cancer
Radium-223 in Biochemically Recurrent Prostate Cancer
Background: Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically recurrent prostate cancer.
- Trial name
- NCT04206319
- Testing
- Radium-223, 18F Sodium Fluoride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Osteoporosis
Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )
Multi-center,double blind randomized phase III placebo controlled study in 250 men with histologically proven prostate cancer with out bone metastases who are beginning ADT therapy and who will receive concomitant treatment with…
- Trial name
- NCT00236002
- Testing
- Alendronate
- Volunteers
- 182 people
- Sponsor
- Canadian Urology Research Consortium
Prostate Cancer
Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Vitamin D and soy extract may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment.
- Trial name
- NCT00499408
- Testing
- Vitamin D, soy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer
RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nordihydroguaiaretic acid…
- Trial name
- NCT00313534
- Testing
- masoprocol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04423211
- Testing
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography
- Where
- 341 sites in United States
- Volunteers
- 804 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non-Metastatic Prostate Cancer
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were…
- Trial name
- Capri (NCT00673205)
- Testing
- Bicalutamide
- Where
- 128 sites in Australia, Austria and 14 more
- Volunteers
- 3,588 people
- Sponsor
- AstraZeneca
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma
RElugolix VErsus LeUprolide Cardiac Trial
This clinical trial investigates the impact of prostate cancer treatment, specifically androgen deprivation therapy (ADT), on the heart and coronary vessels among men with localized, non-metastatic prostate cancer undergoing…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- REVELUTION (NCT05320406)
- Testing
- Radiation therapy, Leuprolide, Relugolix
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Emory University
Cancer, Cataract
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation…
- Conditions
- Cancer, Cataract, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00925600
- Testing
- Denosumab
- Where
- 172 sites in United States, Australia and 16 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Prostate Cancer, Non-metastatic Prostate Cancer
PROState Pathway Embedded Comparative Trial
The proposal will explore a trial design called the cohort-multiple RCT (cmRCT) or as it has been recently coined, the Trials WithIn Cohorts (TWICS) design.
- Conditions
- Prostate Cancer, Non-metastatic Prostate Cancer, Metastatic Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- IP3-PROSPECT (NCT04400656)
- Where
- 3 sites in United Kingdom
- Volunteers
- 139 people
- Sponsor
- Imperial College London
Non-metastatic Prostate Cancer
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically…
- Trial name
- NCT00657904
- Testing
- Bicalutamide
- Where
- 85 sites in United States, Canada
- Volunteers
- 3,618 people
- Sponsor
- AstraZeneca
Prostate Cancer
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy, such as bicalutamide, leuprolide, and goserelin, may lessen the amount of androgens made by the body.
- Trial name
- NCT00771017
- Testing
- GVAX prostate cancer vaccine, bicalutamide, goserelin
- Sponsor
- Eastern Cooperative Oncology Group
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
This trial performs user testing of a mobile-friendly patient history collection and genetic education tool to improve healthcare providers' understanding of prostate cancer genetic testing.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Trial name
- NCT04447703
- Testing
- Interview, Internet Based Intervention, Survey Administration
- Where
- 5 sites in United States
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Prostate Cancer
External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)
This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent…
- Trial name
- NCT05146973
- Testing
- 177Lu-DOTA-TLX591
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Biochemically Recurrent Prostate Cancer
A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Researchers are looking for a better way to treat men who have biochemically recurrent hormone-naïve prostate cancer. Hormone-naïve prostate cancer is a prostate cancer that has not yet been treated with hormonal therapy…
- Trial name
- ARAMON (NCT05526248)
- Testing
- Darolutamide(BAY1841788, Nubeqa), Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Bayer
Non-metastatic Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
This is an observational study in which data will be collected and studied from men with non-metastatic prostate cancer (nmPC) who received their usual treatment with 'androgen receptor inhibitors' (ARIs) including darolutamide…
- Trial name
- ARENA (NCT06204302)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- Bayer
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
- Trial name
- NCT04777071
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- University of Washington
Prostate Cancer
A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA
Patients will take 150 mg of GSE product by mouth twice daily and will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year.
- Trial name
- NCT03087903
- Testing
- Grape Seed Extract
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Colorado, Denver
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
This phase II trial is studying how well fenretinide works in treating patients with biochemically (rising PSA level) recurrent hormone-naïve (no previous hormone therapy) prostate cancer.
- Trial name
- NCT00080899
- Testing
- fenretinide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)